Committee for Medicinal Products for Human Use (CHMP) issues positive recommendation for license extension of darunavir / cobicistat (Rezolsta)

CHMP recommended a license extension for treatment of human immunodeficiency virus‑1 (HIV‑1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg).

Source:

European Medicines Agency